The Year at the FDA – 2025 Popular Reads on JD Supra

For your reference, here's a look at some of the most widely read updates, guidance, and commentary covering the United States Food and Drug Administration and related matters published on JD Supra during 2025:

1. Trump Signals Cannabis Rescheduling: Schedule III Marijuana Decision Expected Soon – by Shawn Hauser at Vicente
2. The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions – by Andrew Ittleman at Fuerst Ittleman David & Joseph (FIDJ)
3. FDA Update: Current Guidelines for Semaglutide and Tirzepatide Compounding – by Keith Lefkowitz at Hendershot Cowart P.C.
4. FDA Regulatory Updates for Summer 2025: Food, Supplements, and Cosmetics – by Bryana Bowman, Claudia Lewis, Richard Starr, Nicole Yapp at Venable
5. GLP-1 Weight-Loss Drugs Off Shortage List; Deadlines to Stop Compounding – by Judi Abbott Curry, Marina Plotkin, Megan Pollastro at Harris Beach Murtha
6. DOJ Settlement With Medical Technology Company Signals Expanding Cybersecurity FCA Risk for Life Sciences Companies – by attorneys at Skadden
7. Complete Response Letter, Warning Letter and Shareholder Lawsuit Follow FDA Data Integrity Findings – by Elizabeth Caruso, Natasha Leskovsek, and Sonia Nath at Cooley
8. Food and Beverage News and Trends - August 2025 – by Maggie Craig, Stefanie Fogel, Sharon Lindan Mayl, and Amy Pressman at DLA Piper
9. FDA Announced Removal of Tirzepatide from the Drug Shortage List – by attorneys at Wilson Sonsini
10. Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time – by Andrew Ittleman at Fuerst Ittleman David & Joseph (FIDJ)
11. FDA’s Semaglutide Shortage Resolution: Legal Implications and Risks for Compounding Pharmacies – by

    Amanda Bogle, Carly Eisenberg Hoinacki, and Kendall Kohlmeyer at Sheppard Mullin

12. Recalled Medical Devices: How to Check If You Have One – by attorneys at Searcy Denney
13. Trump’s FDA and USDA: Five Key Issues To Watch in 2025 – by Brian Sylvester at Perkins Coie
14. How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 13, 2025 – by Aydin Harston Ph.D. and Alexander Shaver Ph.D. at Rothwell Figg
15. Under RFK Jr., US Health Policy and FDA Operations May See Major Shifts – by Avia Dunn, Maya Florence, Nicole Grimm, and Rachel Turow at Skadden

+

Follow JD Supra's FDA channel for ongoing analysis and commentary delivered to your inbox as it is published.